Bilbao

• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm … Ended recruitment
  2023-505120-59-00 5 2023-12-19 Moderate to Severe Plaque Psoriasis
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended recruitment
  2022-502593-17-00 5 2023-09-19 Locally advanced or metastatic hormone receptor (HR)-positive, human e
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended recruitment
  2022-502700-78-00 5 2023-09-01 Alopecia areata (AA)
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended recruitment
  2022-500700-22-00 5 2023-05-25 Active Systemic Lupus Erythematosus (SLE)
• ETOP 22-22 ADEPPT: A study of adagrasib for patients with KRASG12C-mutant non-small cell lung cancer (NSCLC), who are elderly or who are unw … Ended recruitment
  2023-510463-35-00 4 2023-04-26 Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years
• ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w … Ended recruitment
  2024-512288-29-00 4 2023-04-11 Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous
• A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast C … Ended recruitment
  2023-505552-22-00 5 2023-02-24 Stage I-III Triple-negative Breast Cancer with residual invasive disea
• A study of ONCOFID-P-B administered intravesically to patients with Carcinoma in Situ of the bladder who have not responded to the standard … Ended recruitment
  2024-512568-72-00 5 2023-02-24 BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T
• An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici … Ended recruitment
  2023-508740-21-00 4 2023-02-15 Non-Small Cell Lung Cancer
• A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO) Ended recruitment
  2022-501744-15-00 5 2023-01-23 Obesity, Overweight
• Study of neoadjuvant patritumab deruxtecan with or without endocrine therapy in previously untreated patients – VALENTINE trial Ended recruitment
  2023-503403-28-00 4 2022-11-25 treatment naïve patients with HR+/HER2-negative high-risk early breast
• Study of pembrolizumab, lenvatinib and chemotherapy combination in first line lung cancer Ended recruitment
  2024-511412-25-00 4 2022-11-07 First line treatment for extensive-stage small cell lung cancer small
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients with Paroxysmal Nocturnal … Ended recruitment
  2023-509657-31-00 5 2022-08-24 Paroxysmal nocturnal haemoglobinuria (PNH)
• Phase II study to evaluate diarrhoea discontinuations at 3 cycles in patients with early-stage HER2 positive, hormone receptor positive brea … Ended recruitment
  2024-514630-21-00 4 2022-08-11 HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• A research study to evaluate the activity of Sotorasib for the treatment of patients with non-operable non-small cell lung cancer with a KRA … Ended recruitment
  2024-511268-10-00 4 2022-05-25 Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cel
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of LG IR NMIBC Ended recruitment
  2023-506680-34-00 5 2022-03-24 Non-Muscle Invasive Bladder Cancer
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca … Ended recruitment
  2023-509631-37-00 5 2022-01-18 "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended recruitment
  2024-510735-21-00 5 2021-11-26 Atherosclerotic cardiovascular disease (ASCVD)
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus (ALLEGORY) Ended recruitment
  2023-504774-38-00 5 2021-11-04 Systemic Lupus Erythematosus (SLE)
• Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti … Ended recruitment
  2024-516039-28-00 6 2021-09-28 Spontaneous Coronary Artery Dissection.

Showing 97–120 of 165 trials